【摘要】 目的评价培美曲塞联合奈达铂应用于一线化疗失败的晚期子宫内膜癌患者的疗效与安全性。方法 12例既往紫杉醇+卡铂一线化疗失败的晚期子宫内膜癌患者,接受培美曲塞二钠500 mg/m2+奈达铂80 mg/m2治疗。入选患者至少接受2个周期以上化疗,最多接受6个周期化疗。结果共12例患者接受培美曲塞联合奈达铂治疗,部分缓解3例(25.0%),肿瘤稳定5例(41.7%)。不良反应主要为骨髓抑制(Ⅲ/Ⅳ度),贫血占25.0%,中性粒细胞下降占41.7%,血小板减少占25.0%,无治疗相关死亡。结论对于既往一线化疗失败晚期子宫内膜癌,国产培美曲塞值得临床试用。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of pemetrexed plus nedaplatin in treatment of patients with advanced endometrial carcinoma previously failed in chemotherapy.Methods Twelve patients with advanced endometrial carcinoma failed in previous treatment with paclitaxel plus carboplatin received pemetrexed 500 mg/m2 and nedaplatin 75 mg/m2.All eligible patients received 2 cycles of chemotherapy at least and 6 cycles chemotherapy at most.Results Total 12 patients received pemetrexed and nedaplatin.Three patients(25.0%) had partial response and five patients(41.7%) had stable disease.The principal toxic reactions were myelosuppression(grade 3 and 4),including anemia in 25.0%,neutropenia in 41.7% and thrombocytopenia in 25.0%.No treatment-related death was reported.Conclusion Pemetrexed may be promising for advanced endometrial carcinoma failed in previous treatment with chemotherapy.更多还原